Literature DB >> 16289693

Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis.

Kazuhiro Komura, Manabu Fujimoto, Takashi Matsushita, Kenzo Kaji, Miki Kondo, Takashi Hirano, Hidemitsu Orito, Mayuka Horikawa, Yasuhito Hamaguchi, Minoru Hasegawa, Kazuhiko Takehara, Shinichi Sato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16289693     DOI： 10.1016/j.jdermsci.2005.09.004

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN： 0923-1811            Impact factor:   4.563


× No keyword cloud information.
  11 in total

Review 1.  Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 2.  A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Authors:  Minoru Satoh; Shin Tanaka; Angela Ceribelli; S John Calise; Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

3.  More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.

Authors:  Iago Pinal-Fernandez; Christopher A Mecoli; Maria Casal-Dominguez; Katherine Pak; Yuji Hosono; Julio Huapaya; Wilson Huang; Jemima Albayda; Eleni Tiniakou; Julie J Paik; Cheilonda Johnson; Sonye K Danoff; Andrea M Corse; Lisa Christopher-Stine; Andrew L Mammen
Journal:  Neurology       Date:  2019-10-08       Impact factor: 9.910

Review 4.  Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay.

Authors:  Li Wang; Li Huang; Yang Yang; Huan Chen; Yanjuan Liu; Ke Liu; Meidong Liu; Yizhi Xiao; Hui Luo; Xiaoxia Zuo; Yisha Li; Xianzhong Xiao; Huali Zhang
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

5.  Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.

Authors:  Puja Srivastava; Sanjay Dwivedi; Ramnath Misra
Journal:  Rheumatol Int       Date:  2016-05-14       Impact factor: 2.631

Review 6.  Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology.

Authors:  V Madan; H Chinoy; C E M Griffiths; R G Cooper
Journal:  Clin Exp Dermatol       Date:  2009-07       Impact factor: 3.470

Review 7.  Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.

Authors:  Paige W Wolstencroft; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

8.  Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan.

Authors:  Hidenaga Kawasumi; Takahisa Gono; Yasushi Kawaguchi; Masataka Kuwana; Hirotaka Kaneko; Yasuhiro Katsumata; Sayuri Kataoka; Masanori Hanaoka; Hisashi Yamanaka
Journal:  Biomed Res Int       Date:  2016-01-26       Impact factor: 3.411

9.  Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.

Authors:  Yasuhito Hamaguchi; Manabu Fujimoto; Takashi Matsushita; Kenzo Kaji; Kazuhiro Komura; Minoru Hasegawa; Masanari Kodera; Eiji Muroi; Keita Fujikawa; Mariko Seishima; Hidehiro Yamada; Ryo Yamada; Shinichi Sato; Kazuhiko Takehara; Masataka Kuwana
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

10.  The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Mona Shah; Gulnara Mamyrova; Adam M Huber; Madeline Murguia Rice; Ira N Targoff; Frederick W Miller
Journal:  Medicine (Baltimore)       Date:  2013-07       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.